Major histocompatibility complex phenotypes influence serum testosterone concentration.
OBJECTIVE
(a) To confirm our earlier observation that the phenotype HLA-DR4,7 occurs with higher frequency in male patients with rheumatoid arthritis (RA) than in female patients. (b) To test the hypothesis that DR7 is associated with low normal serum testosterone (Te) levels in healthy males; this might explain the increased frequency of DR4,7 in male patients since there appears to be a relationship between low serum Te and RA. (c) To characterize the association between HLA alleles and serum Te concentration in healthy males.


METHODS
An additional 82 Newfoundland (NF) RA patients were HLA-DR typed and, combined with our earlier data and data from the 11th International Histocompatibility Workshop, gave HLA-DR and sex information on 373 RA patients. Ninety-four healthy NF males were typed for HLA, the microsatellite marker TNFa (located close to the tumour necrosis factor alpha gene) and complement factor B (BF). An additional 38 males were included, selected partly based on their HLA-B type.


RESULTS
We confirmed our earlier finding of a higher frequency of HLA-DR4,7 in male RA patients compared with female RA patients (P<0.01). Contrary to our expectations we found that DR7 was associated with higher than mean values of Te as were B5, B27, DR1, TNFa7 and BF F positivity. Conversely, low Te concentrations were found in men with B15, DR2, DR5, TNFa5 and who were BF F negative. In 28 male 'early-onset' RA patients we did not find an increased frequency of HLA alleles associated with low Te levels as compared with the frequency in 41 'late-onset' patients, suggesting that if low Te level is a risk factor and is present before onset of RA then the level cannot be explained by an association between Te level and major histocompatibility complex (MHC) phenotype.


CONCLUSIONS
This study indicates that a man's MHC phenotype may influence his serum Te concentration, but the relationship of this, if any, to the pathogenesis of RA remains an area of speculation.
Larsen
B
B
Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland, Canada.
King
C A
CA
Simms
M
M
Skanes
V M
VM
D000328:Adult; D017668:Age of Onset; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000235:genetics; D011415:Complement Factor B / Q000235:genetics / Q000502:physiology; D005260:Female; D005838:Genotype; D015235:HLA-B Antigens / Q000235:genetics / Q000502:physiology; D015804:HLA-DR4 Antigen / Q000235:genetics / Q000502:physiology; D015809:HLA-DR7 Antigen / Q000235:genetics / Q000502:physiology; D006801:Humans; D008285:Major Histocompatibility Complex; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D013739:Testosterone / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000502:physiology
D015235:HLA-B Antigens; D015804:HLA-DR4 Antigen; D015809:HLA-DR7 Antigen; D014409:Tumor Necrosis Factor-alpha; D013739:Testosterone; D011415:Complement Factor B